Patient characteristics and adverse events (AEs) of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) in real world settings.

e18026 Background: The growing number of TKIs available for CML increases complexity in choosing therapy in non-research settings. This study aims to determine patient (pt) characteristics & emergent AEs that might underlie treatment choices. Methods: TKI treatment episodes for adult CML pts from 1/2008 - 7/2014 were identified in the MarketScan Commercial, Medicaid, and Medicare supplemental databases. Pts were required to have ≥ 6 mos of enrollment prior to TKI episodes. Analyses were retrospective. Median duration of treatment was assessed using the Kaplan-Meier method. Results: 4,166 TKI treatment episodes for CML were identified. Imatinib (IM) was most commonly used 1st line, dasatinib (DAS) & nilotinib (NIL) 2nd line, and bosutinib (BOS) and ponatinib (PON) 3rd line. BOS pts had the most previous TKI episodes and were furthest from initial diagnosis. They were the oldest, had the highest Charlson Comorbidity Index (CCI), the most histories of vascular occlusive (VO) conditions, kidney diseases, & pl...